Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 5;10(17):4011.
doi: 10.3390/jcm10174011.

A Multicenter Randomized Controlled Prospective Study to Assess Efficacy of Laparoscopic Electrochemotherapy in the Treatment of Locally Advanced Pancreatic Cancer

Francesco Izzo  1 , Vincenza Granata  2 , Roberta Fusco  3 , Valeria D'Alessio  3 , Antonella Petrillo  2 , Secondo Lastoria  4 , Mauro Piccirillo  1 , Vittorio Albino  1 , Andrea Belli  1 , Guglielmo Nasti  5 , Antonio Avallone  5 , Renato Patrone  6 , Francesca Grassi  7   8 , Maddalena Leongito  1 , Raffaele Palaia  1
Affiliations

A Multicenter Randomized Controlled Prospective Study to Assess Efficacy of Laparoscopic Electrochemotherapy in the Treatment of Locally Advanced Pancreatic Cancer

Francesco Izzo et al. J Clin Med. .

Abstract

Background: Eighty percent of patients with pancreatic adenocarcinoma present a locally advanced or metastatic disease at diagnosis and are not eligible for surgery if not with palliative intent. In cases of locally advanced disease (LAPC), the combination of chemo and radiotherapy is the only therapeutic option and correlates with a median survival of 15 months (10 months without treatment), with partial remission of disease in 50% of cases. The feasibility and safety of Electrochemotherapy (ECT) have been demonstrated in the treatment of deep tumors.

Aim: The aim of the study is to evaluate the efficacy of electrochemotherapy (ECT) followed by conventional systemic treatment compared to the only conventional systemic treatment in LAPC in terms of objective response and overall survival.

Patients and methods: This study is a phase IIb prospective multicenter randomized controlled trial with two arms. The study will include 90 patients: 45 in the control group and 45 in the experimental group. Patients with LAPC in the control arm will receive conventional chemotherapy (FOLFOXIRI). Patients with LAPC in the experimental arm will be subjected to Electrochemotherapy and subsequently to FOLFOXIRI. The objective response at 30, 90, and 180 days from treatment will be based on the computed tomography (CT), magnetic resonance (MR), and positron emission tomography/CT response (PET/CT). The objective long-term treatment response will be evaluated with the modified response evaluation criteria in solid tumors (m-RECIST) criteria, which will take into account the difference in vascularization, determined by the images obtained by CT and MR of the tumor treated before and after ECT.

Conclusions: Not resectable liver metastasis, pancreatic tumors, and locally advanced renal carcinomas can be treated with laparoscopic electrodes. ECT could represent an effective therapeutic option for patients not eligible for surgery susceptible to be managed only with palliative therapies.

Keywords: electroporation; laparoscopic electrochemotherapy; locally advanced pancreatic.

PubMed Disclaimer

Conflict of interest statement

Roberta Fusco and Valeria D’Alessio work for IGEA SpA.

Figures

Figure 1
Figure 1
Trial design flowchart.
See this image and copyright information in PMC

References

    1. Belehradek M., Domenge C., Luboinski B., Orlowski S., Belehradek J., Mir L.M. Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer. 1993;72:3694–3700. doi: 10.1002/1097-0142(19931215)72:12<3694::AID-CNCR2820721222>3.0.CO;2-2. - DOI - PubMed
    1. Izzo F., Granata V., Fusco R., D’Alessio V., Petrillo A., Lastoria S., Piccirillo M., Albino V., Belli A., Tafuto S., et al. Clinical Phase I/II Study: Local Disease Control and Survival in Locally Advanced Pancreatic Cancer Treated with Electrochemotherapy. J. Clin. Med. 2021;10:1305. doi: 10.3390/jcm10061305. - DOI - PMC - PubMed
    1. Mir L., Belehradek M., Domenge C., Orlowski S., Poddevin B., Belehradek J., Schwaab G., Luboinski B., Paoletti C. Electrochemotherapy, a new antitumor treatment: First clinical trial. CR Acad. Sci. III. 1991;313:613–618. doi: 10.1002/1097-0142(19931215)72:123.0.co;2-2. - DOI - PubMed
    1. Marty M., Sersa G., Garbay J.R., Gehl J., Collins C.G., Snoj M., Billard V., Geertsen P.F., Larkin J.O., Miklavčič D., et al. Electrochemotherapy—An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur. J. Cancer Suppl. 2006;4(Suppl. S4):3–13. doi: 10.1016/j.ejcsup.2006.08.002. - DOI
    1. Mir L.M., Gehl J., Sersa G., Collins C.G., Garbay J.-R., Billard V., Geertsen P.F., Rudolf Z., O’Sullivan G.C., Marty M. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. Eur. J. Cancer Suppl. 2006;4:14–25. doi: 10.1016/j.ejcsup.2006.08.003. - DOI

LinkOut - more resources